Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii.

Pharmaceutics · 2022 · PMC8778299 · PMID 35057026

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp ≤ 0.001actually significant

Note: no significant ( ns ) = p > 0.05, significant = * p ≤ 0.05, very significant = ** p ≤ 0.01, and highly significant = *** p ≤ 0.001.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and <i>N</i>-Acetylcysteine against Tobramycin-Resistant <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Acinetobacter baumannii</i>.

The sentences